These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 16998940)

  • 21. Polycythemia vera is not initiated by JAK2V617F mutation.
    Nussenzveig RH; Swierczek SI; Jelinek J; Gaikwad A; Liu E; Verstovsek S; Prchal JF; Prchal JT
    Exp Hematol; 2007 Jan; 35(1):32-8. PubMed ID: 17198871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders.
    Lieu CH; Wu HS; Hon YC; Tsai WH; Yang CF; Wang CC; Lin YC; Shih CH; Hsu HC
    Intern Med J; 2008 Jun; 38(6):422-6. PubMed ID: 18336541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.
    Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N
    Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
    Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
    Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
    Bousquet M; Le Guellec S; Quelen C; Rigal-Huguet F; Delsol G; Brousset P
    Hum Pathol; 2006 Nov; 37(11):1458-64. PubMed ID: 16949922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation.
    Tan AY; Westerman DA; Dobrovic A
    Am J Clin Pathol; 2007 Jun; 127(6):977-81. PubMed ID: 17509995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.
    Horn T; Kremer M; Dechow T; Pfeifer WM; Geist B; Perker M; Duyster J; Quintanilla-Martinez L; Fend F
    J Mol Diagn; 2006 Jul; 8(3):299-304. PubMed ID: 16825501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
    Aboudola S; Murugesan G; Szpurka H; Ramsingh G; Zhao X; Prescott N; Tubbs RR; Maciejewski JP; Hsi ED
    Am J Surg Pathol; 2007 Feb; 31(2):233-9. PubMed ID: 17255768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood.
    Stevenson WS; Hoyt R; Bell A; Guipponi M; Juneja S; Grigg AP; Curtis DJ; Scott HS; Szer J; Alexander WS; Tuckfield A; Roberts AW
    Pathology; 2006 Aug; 38(4):336-42. PubMed ID: 16916724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms.
    Trifa AP; Cucuianu A; Petrov L; Urian L; Militaru MS; Dima D; Pop IV; Popp RA
    Ann Hematol; 2010 Oct; 89(10):979-83. PubMed ID: 20422415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders.
    Speletas M; Katodritou E; Daiou C; Mandala E; Papadakis E; Kioumi A; Ritis K; Korantzis I
    Leuk Res; 2007 Aug; 31(8):1053-62. PubMed ID: 17045648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.
    Pietra D; Li S; Brisci A; Passamonti F; Rumi E; Theocharides A; Ferrari M; Gisslinger H; Kralovics R; Cremonesi L; Skoda R; Cazzola M
    Blood; 2008 Feb; 111(3):1686-9. PubMed ID: 17984312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. JAK2 (V617F) mutation is not associated with thrombosis in Behcet syndrome.
    Ar MC; Hatemi G; Ekizoğlu S; Bilgen H; Saçli S; Buyru AN; Soysal T; Ülkü B; Yazici H
    Clin Appl Thromb Hemost; 2012 Jul; 18(4):421-6. PubMed ID: 22203033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Usefulness of real-time semi-quantitative PCR, JAK2 MutaScreen kit for JAK2 V617F screening].
    Chae H; Lee JH; Lim J; Jung SW; Kim M; Kim Y; Han K; Cho BS; Cho SG; Lee JW; Min WS
    Korean J Lab Med; 2009 Jun; 29(3):243-8. PubMed ID: 19571623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is the JAK2 V617F mutation a hallmark for different forms of thrombosis?
    Zerjavic K; Zagradisnik B; Stangler Herodez S; Lokar L; Glaser Krasevac M; Kokalj Vokac N
    Acta Haematol; 2010; 124(1):49-56. PubMed ID: 20616539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
    Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
    Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases.
    Rapado I; Albizua E; Ayala R; Hernández JA; Garcia-Alonso L; Grande S; Gallardo M; Gilsanz F; Martinez-Lopez J
    Ann Hematol; 2008 Sep; 87(9):741-9. PubMed ID: 18575865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders.
    Chen Q; Lu P; Jones AV; Cross NC; Silver RT; Wang YL
    J Mol Diagn; 2007 Apr; 9(2):272-6. PubMed ID: 17384221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
    Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J
    Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.